$AMRS & Johnson & Johnson $JNJ via Janssen. Recently entered into research agreement with commercial license option with Janssen Biotech, facilitated by Johnson & Johnson Innovation, to use Amyris’s µPharm platform for rapid integrated discovery and production of therapeutic compounds thereby opening a new area of compounds previously not accessible for new drug discovery. “We expect to sign one more collaboration by the end of the year, ending at the high-end of our range, to develop a library of natural and natural like of therapeutic compounds, which nature has the potential to provide and we have the ability to produce.” http://www.biofuelsdigest.com/bdigest/2016/08/14/amyris-the-new-colossus-aims-to-unlock-its-golden-door/
News 
Market Data 
Discover 
